APR 28, 2022 12:35 PM PDT

Keto Molecule Shows Promise for Treating Colorectal Cancer

WRITTEN BY: Annie Lennon

A molecule produced when on low-carbohydrate ketogenic diets suppresses the growth of colorectal tumors in the lab. The corresponding study was published in Nature

Colorectal cancer kills around 50,000 people in the US per year, making it the third leading cause of cancer mortality in the country. Lifestyle factors including alcohol use, obesity, red meat consumption, and low-fiber yet high sugar diets are linked to a greater risk of the condition. 

In the present study, researchers sought to investigate the effects of different diets on colorectal tumor growth. To do so, they put six groups of mice on diets with varying fat-to-carb ratios and induced colorectal tumors via a standard chemical technique. 

They found that the diets with the least amount of carbs at 90% fat-carb ratios- whether using pig lard or soybean oil- were best able to prevent tumor growth. Their protective effect was notable even after colorectal tumors had started growing. On the other hand, animals on other diets, including low fat and high carbs, developed tumors. 

The researchers confirmed from further experiments that tumor suppression from low-carb diets was linked to slower production of new epithelial cells lining the colon. This, they found, was in turn linked to increased levels of beta-hydroxybutyrate (BHB), a molecule produced by the liver as part of a ‘starvation response’, and that is typically triggered by keto diets. 

In keto diets, BHB often works as an alternative fuel source for key organs. However, in this study, the researchers found that it is also a potent growth-slowing signal. 

In further experiments, the researchers were able to replicate the antitumor effects of keto diets on mice by giving them BHB supplements either via water or infusion. In doing so, they found that BHB slows down the growth of gut-lining cells by activating a surface receptor on colorectal tumors called Hcar2. This then activates the growth-slowing gene, Hopx. 

The researchers note that not all colorectal tumor cells express Hcar2 and Hopx, meaning that not all colorectal tumors will respond to this treatment. This, they say, means that BHB supplementation could at least offer insight into alternative treatment methods.

The researchers say that while these findings are encouraging, further research is needed before they may inform treatment options. 

 

Sources:  NatureScience Daily

 

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
AUG 11, 2022
Cell & Molecular Biology
From sample collection straight to RT-qPCR
AUG 11, 2022
From sample collection straight to RT-qPCR
Skip the nucleic acid purification step in your cancer detection workflow. Learn more about how Thermo Fisher Scientific ...
JUN 17, 2022
Cannabis Sciences
Projected Increases in Cannabis Use in States Legalizing Recreational Cannabis
JUN 17, 2022
Projected Increases in Cannabis Use in States Legalizing Recreational Cannabis
A study published in the scientific journal Addiction found that people will be more likely to use cannabis as their sta ...
JUN 27, 2022
Drug Discovery & Development
Potential Gene Targets Identified for Treating Deafness
JUN 27, 2022
Potential Gene Targets Identified for Treating Deafness
Researchers have identified three mutations of the MINAR2 gene that are linked to deafness. They say that the mutations ...
JUL 04, 2022
Cannabis Sciences
Study calls for Improved Cannabis Product Labeling Practices
JUL 04, 2022
Study calls for Improved Cannabis Product Labeling Practices
Large scale study of cannabis product labeling highlights a critical need for more informative and accurate product desc ...
JUL 12, 2022
Drug Discovery & Development
Nitric Oxide Reduces Hospital Stay of Pregnant Women with COVID-19
JUL 12, 2022
Nitric Oxide Reduces Hospital Stay of Pregnant Women with COVID-19
High-dose nitric oxide can reduce the length of hospital and ICU stay, as well as the need for supplemental oxygen, amon ...
AUG 11, 2022
Clinical & Molecular DX
New Tuberculosis Vaccine Enters Phase III Clinical Trial
AUG 11, 2022
New Tuberculosis Vaccine Enters Phase III Clinical Trial
Tuberculosis is a disease caused by the bacterium Mycobacterium tuberculosis. It is spread through the air when a person ...
Loading Comments...